Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Rises By 30.7%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 597,300 shares, an increase of 30.7% from the December 31st total of 457,100 shares. Based on an average daily trading volume, of 421,900 shares, the short-interest ratio is currently 1.4 days. Approximately 22.4% of the company’s shares are short sold.

Aligos Therapeutics Stock Performance

Shares of ALGS traded up $2.06 during trading hours on Friday, hitting $25.80. The stock had a trading volume of 374,497 shares, compared to its average volume of 301,097. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $46.80. The firm has a market cap of $92.62 million, a P/E ratio of -1.94 and a beta of 2.50. The company’s fifty day simple moving average is $32.67 and its 200 day simple moving average is $19.10.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The firm had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the prior year, the firm earned ($10.25) earnings per share. As a group, sell-side analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Institutional Trading of Aligos Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. AlphaMark Advisors LLC boosted its stake in shares of Aligos Therapeutics by 1,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after purchasing an additional 1,000 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of Aligos Therapeutics during the fourth quarter valued at about $107,000. Finally, Drive Wealth Management LLC acquired a new position in shares of Aligos Therapeutics in the fourth quarter worth about $916,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).